Continuous Glucose Monitoring (CGM) Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Application (Diabetic Patients, Critical Care Patients), By End User Industry (Hospitals, Diagnostic Centers and Clinics, Home care), And By Geography - Forecasts From 2023 To 2028
- Published: September 2025
- Report Code: KSI061611519
- Pages: 142
Continuous Glucose Monitoring (CGM) Market Size:
The Continuous Glucose Monitoring (CGM) Market is expected to grow from USD 8.984 billion in 2025 to USD 17.119 billion in 2030, at a CAGR of 13.76%.
Continuous Glucose Monitoring (CGM) Market Key Highlights:
- The primary growth driver for Continuous Glucose Monitoring (CGM) systems is the rising global prevalence of diabetes and prediabetes, which necessitates more effective, real-time management of blood glucose levels.
- Regulatory approvals, particularly by the U.S. Food and Drug Administration (FDA) and the European Commission, have expanded CGM use from solely Type 1 diabetes patients to include the broader Type 2 population and even individuals using only basal insulin, a critical growth catalyst.
- Technological advancements, including enhanced accuracy, extended sensor wear time, and miniaturized, all-in-one designs, directly improve patient convenience and reduce the logistical burden, thereby increasing user adoption.
- The integration of CGM data with advanced insulin delivery systems, such as automated insulin pumps, is a significant demand generator, as it creates an "ecosystem" that simplifies and automates diabetes management.
- The expansion of insurance coverage and favorable reimbursement policies for CGM devices in major markets, such as the U.S. and Europe, directly reduces the financial barrier for patients, accelerating market penetration and demand.
The Continuous Glucose Monitoring (CGM) market is a transformative segment of the medical device industry, fundamentally altering how individuals manage diabetes. CGM systems provide real-time, minute-by-minute glucose readings from the interstitial fluid, offering a more complete picture of glucose trends than traditional fingerstick blood glucose meters. This continuous flow of data empowers patients and healthcare providers to make timely, informed decisions regarding diet, exercise, and insulin dosage. The market's evolution is directly tied to the growing global burden of diabetes, a condition that the World Health Organization and other public health bodies identify as a major health challenge. CGM devices represent a paradigm shift from reactive, intermittent monitoring to proactive, continuous management, addressing the limitations of conventional methods and improving health outcomes. The market's dynamics are shaped by technological innovation, regulatory milestones, and the expansion of access to these life-changing devices.
Continuous Glucose Monitoring (CGM) Market Growth Drivers vs. Challenges
Drivers:
The escalating global prevalence of diabetes and prediabetes primarily propels the Continuous Glucose Monitoring (CGM) market growth. The International Diabetes Federation's data on rising diabetes rates underscores a growing patient population that requires more sophisticated tools for glycemic control. This epidemiological trend directly fuels demand for effective management solutions beyond traditional fingerstick testing, which only provides a snapshot in time. CGM systems, by providing continuous data, enable users to identify trends, understand the impact of food and activity, and prevent dangerous hypoglycemic or hyperglycemic events. The increasing focus on preventative care and the long-term economic burden of diabetes-related complications, such as cardiovascular disease and kidney failure, further incentivize the adoption of proactive monitoring technologies like CGM.
A second, powerful driver is the expansion of clinical indications and regulatory clearances. Historically, CGM was largely confined to Type 1 diabetes patients. However, regulatory bodies, including the U.S. Food and Drug Administration (FDA), have broadened clearances to include individuals with Type 2 diabetes who use basal insulin, and even for non-insulin-dependent patients. This expansion multiplies the addressable market size by a significant margin. The FDA's clearance of devices like Abbott's FreeStyle Libre for use by non-insulin-using individuals with diabetes is a direct catalyst for increased demand within a new and substantial patient segment. This trend, coupled with growing physician endorsement of CGM for a wider range of patients, moves the technology from a niche solution to a standard of care for a broader spectrum of the diabetic population.
Challenges:
The Continuous Glucose Monitoring (CGM) market faces a primary challenge in the form of cost and reimbursement limitations. While the clinical benefits of CGM are well-documented, the high upfront cost of sensors and transmitters can be a significant barrier for patients and healthcare systems. In markets where insurance coverage or government reimbursement is limited, a substantial portion of the patient population cannot afford the technology. This creates a supply-side challenge for manufacturers and a demand-side constraint for patients.
However, this challenge simultaneously presents a key opportunity. As the demand for more affordable solutions grows, manufacturers are compelled to innovate on their cost structure. This includes developing longer-wear sensors, which reduce the per-day cost for patients, and streamlining manufacturing processes. The market opportunity also lies in expanding reimbursement coverage. Industry players are actively engaging with insurance companies, government health agencies, and policymakers to demonstrate the long-term cost savings of CGM, arguing that improved glycemic control reduces hospitalizations and the treatment of diabetes-related complications. Successful advocacy for broader reimbursement policies, such as the Centers for Medicare & Medicaid Services (CMS) expansion of coverage in the U.S., acts as a powerful catalyst for demand and market growth. The market can also capitalize on the opportunity to serve the prediabetic and non-diabetic wellness markets, which are not currently addressed by most reimbursement policies, by developing a separate, lower-cost product line.
Supply Chain Analysis
The CGM market's supply chain is a complex global network with multiple dependencies. The production of a CGM system requires the sourcing of highly specialized components, including biosensors, micro-electronic components for transmitters, and polymer-based materials for the disposable sensors and applicators. Biosensor electrodes, which contain enzymes like glucose oxidase, are a critical and sensitive component. Key production hubs for these electronic and medical components are geographically diverse, with significant manufacturing operations in countries like the US, Europe, and various parts of Asia.
Logistical complexities stem from the need to manage a cold chain for certain components and ensure sterility and quality control for devices that are implanted or worn on the body. Dependencies are particularly pronounced in the sourcing of semiconductor chips for the transmitters and receivers, which are susceptible to global supply chain shocks. The production of a single CGM device requires a high degree of vertical integration or a robust network of specialized suppliers. The reliance on these global hubs means that geopolitical events, trade policies, and logistical disruptions can directly impact production capacity and lead times, affecting the market's ability to meet escalating demand.
Government Regulations
Government regulations are a foundational pillar of the CGM market, directly shaping product development, market access, and patient adoption. Regulatory bodies dictate the safety, efficacy, and clinical claims that manufacturers can make, which in turn influences demand by establishing trust and expanding product applications.
|
Jurisdiction |
Key Regulation / Agency |
Market Impact Analysis |
|---|---|---|
|
United States |
U.S. Food and Drug Administration (FDA) |
The FDA's classification of CGMs and its 510(k) and PMA approval processes are a critical market gatekeeper. The FDA's decision to classify certain CGMs as non-adjunctive (allowing for treatment decisions without confirmatory fingerstick) was a watershed moment that directly increased demand by simplifying patient use and making the technology more clinically viable. Subsequent clearances for broader patient populations, such as those with Type 2 diabetes on basal insulin, have also dramatically expanded the addressable market, driving a substantial increase in demand. |
|
European Union |
Medical Device Regulation (MDR) (EU) 2017/745 and CE Mark |
The MDR imposes stricter requirements on medical device manufacturers operating in the EU. This regulation mandates a higher level of clinical evidence and post-market surveillance. While presenting a regulatory hurdle, compliance with MDR is essential for market access and instills a high degree of confidence in the product's safety and effectiveness. The CE mark signifies conformity with these regulations, which is a pre-requisite for sales and directly impacts market demand by establishing a baseline of trust for healthcare providers and patients across the EU. |
|
China |
National Medical Products Administration (NMPA) |
The NMPA regulates the market in China, a high-growth region. The NMPA's processes, which require local clinical trials for most Class II and III devices, create a barrier to entry for international players. However, successful navigation of this process and subsequent market authorization is a key demand driver, as it allows companies to access the vast and rapidly growing Chinese diabetic population. The NMPA's push for local innovation and the prioritization of innovative devices also shape the competitive landscape, creating opportunities for both domestic and foreign companies that can meet these specific regulatory and product development criteria. |
In-Depth Segment Analysis
- By Component: Sensors
The sensor segment is the primary growth engine and a recurring revenue stream for the CGM market. The need for sensors is driven by their disposable nature and the continuous need for replacement. Unlike the one-time purchase of a transmitter or receiver, a patient's demand for sensors is constant and predictable, tied directly to the wear time of the device (e.g., every 10 or 14 days). The sensor is the most critical and technologically sophisticated part of the system, responsible for the actual glucose measurement. Growth drivers for this segment are directly linked to technological improvements that enhance patient experience and clinical utility. These improvements include extended wear time, which reduces the frequency of sensor changes and the associated pain and inconvenience, and increased accuracy, which reduces the need for confirmatory fingersticks. Miniaturization of the sensor and applicator also directly impacts demand by improving patient comfort and discretion, making the technology more appealing to a broader user base. - By End-User Industry: Home Care
The home care segment represents the most significant and fastest-growing end-user for the CGM market. This segment’s expansion is driven by the shift from hospital-based care to self-management at home, a trend accelerated by the convenience and user-friendliness of modern CGM systems. For individuals with diabetes, home use of a CGM system enables real-time, personalized insights into how diet, exercise, and medication impact their glucose levels. This empowers them to take control of their condition in a way that was previously only possible with frequent, painful fingersticks or intermittent medical appointments. The demand for CGM in home care is also a function of the technology's ability to facilitate remote patient monitoring (RPM). Data from a home-based CGM can be shared instantly with a patient’s healthcare provider, allowing for remote consultations and timely adjustments to treatment plans without the need for a physical office visit. This functionality is a powerful catalyst for demand, as it provides a solution that improves clinical outcomes while reducing the logistical burden on both patients and the healthcare system.
Geographical Analysis
- US Market Analysis: The US market for Continuous Glucose Monitoring is the largest globally and is a key driver of innovation and adoption. The market trend is a function of a high prevalence of diabetes, a well-developed healthcare infrastructure, and a robust regulatory environment. The expansion of coverage by major insurers and government programs like Medicare and Medicaid has been a pivotal catalyst, dramatically increasing the number of eligible patients. Competition is intense, driven by major players vying for market share through product innovation, strategic partnerships with insulin pump manufacturers, and aggressive marketing. The US market is also a bellwether for technology adoption, with patient and physician demand for the latest features, such as enhanced accuracy and smartphone integration, influencing global trends.
- Brazil Market Analysis: Brazil's CGM market is developing and presents significant growth potential, driven by a large and growing diabetic population. However, market penetration is constrained by economic factors, including the high cost of devices and limited public reimbursement. The market is concentrated among high-income patients and those with private insurance. Its evolution is contingent on the expansion of public and private insurance coverage, as well as the availability of more affordable devices. Local public health campaigns to raise awareness about diabetes management also contribute to increased demand. The market represents a clear opportunity for companies that can navigate the regulatory landscape and provide products at a price point accessible to a broader segment of the population.
- Germany Market Analysis: Germany's CGM market is highly mature and one of the largest in Europe. A strong healthcare system and favorable reimbursement policies fuel market growth. The statutory health insurance system provides broad coverage for CGM systems for a wide range of diabetes patients, significantly reducing the financial barrier to adoption. The German market is characterized by a high level of technological sophistication, with strong demand for devices that integrate with advanced insulin delivery systems. The country’s focus on long-term health outcomes and a high level of patient and physician education on diabetes management ensures a stable and growing demand for advanced, certified CGM technology.
- Saudi Arabia Market Analysis: The CGM market in Saudi Arabia is emerging, driven by high rates of diabetes and government initiatives to modernize healthcare. The market is primarily concentrated in major urban centers and among high-income individuals. The government’s Vision 2030 program includes a focus on improving public health, which is expected to drive increased investment in technologies like CGM. However, market adoption faces challenges from limited public reimbursement and a reliance on out-of-pocket payments. The market opportunity lies in the growing private healthcare sector and the potential for future government-led public health programs that could expand access and drive significant demand.
- Japan Market Analysis: Japan's CGM market is advanced and driven by a strong focus on clinical excellence and patient-centric design. The market trend is a function of a sophisticated healthcare system, an aging population with a high prevalence of diabetes, and a preference for high-quality, reliable medical devices. The market is also driven by the integration of CGM with insulin pump therapy, as Japanese companies are leaders in both technologies. Japanese regulatory approvals are rigorous, but once a product is approved and gains a foothold, it benefits from strong physician and patient trust. The market's expansion is shaped by a focus on miniaturization and user-friendliness, aligning with a broader consumer electronics trend in the country.
Competitive Environment and Analysis
The competitive landscape of the CGM market is a duopoly dominated by Abbott and Dexcom, with Medtronic and other players holding a competitive, albeit smaller, presence. The primary axis of competition is a combination of product innovation, clinical accuracy, and strategic partnerships.
- Dexcom, Inc.: Dexcom is a leading player in the real-time CGM space, with a strategic focus on innovation, accuracy, and connectivity. Its flagship product is the Dexcom G7, which is a miniaturized, all-in-one sensor and transmitter. The company’s strategic positioning is built on providing a best-in-class, user-friendly experience with superior accuracy and a fast warm-up time. Dexcom’s direct-to-consumer marketing, coupled with its focus on integration with insulin pumps, has been a key growth driver. The company also strategically partners with other technology companies to expand its ecosystem and make its data accessible on a wide range of devices, including smartwatches, which further enhances patient convenience and drives adoption.
- Abbott Laboratories: Abbott is a dominant force in the CGM market, primarily with its FreeStyle Libre family of products. Abbott's strategic positioning is to provide a user-friendly, accessible, and affordable solution. The Libre system, with its sensor that can be scanned with a smartphone, offers a different value proposition from real-time CGMs. Abbott has been particularly successful at expanding its clinical indications and securing reimbursement for a broader patient population, including those who do not use insulin. The company’s focus on a two-week wear sensor and a simpler, lower-cost model has allowed it to achieve massive market penetration in both developed and developing regions, directly fueling demand.
- Medtronic plc: Medtronic is a diversified medical technology company with a strong presence in the diabetes care segment. Its strategic positioning is to provide an integrated "ecosystem" that combines its CGM devices with its advanced insulin pumps and automated insulin delivery systems. This integration is a powerful demand generator, as it offers a closed-loop solution that simplifies diabetes management for patients. Medtronic's MiniMedâ„¢ 780G system, which uses its Guardian Sensor, is a key product in this strategy, as it offers a seamless integration of glucose monitoring and automated insulin delivery. The company leverages its long-standing relationships with healthcare providers and its extensive global footprint to compete effectively.
- Recent Development: In September 2025, Senseonics Holdings, Inc., which develops and manufactures CGM systems, will commercialise and distribute Eversense 365 and future products from Ascensia Diabetes Care, a member of PHC Group, to Senseonics in the U.S. beginning January 1, 2026.
- Recent Development: In August 2025, the U.S. FDA approved Signos, a U.S.-based startup, for the first-ever glucose monitoring system designed specifically for weight management. The company integrates an off-the-shelf Dexcom CGM with AI to offer real-time and personalized insights.
- Recent Development: In August 2024, Abbott partnered with Medtronic to integrate Abbott’s FreeStyle Libre CGM system technology with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.
- Recent Development: In June 2024, the U.S. FDA gave clearance for two new over-the-counter CGM systems – Lingo and Libre Rio, which are based on Abbott's FreeStyle Libre continuous glucose monitoring technology.
Continuous Glucose Monitoring (CGM) Market Segmentation:
- By Component
- Sensors
- Transmitters
- Receivers
- Integrated Insulin Pumps
- By Product Type
- Wearable
- Implantable
- By Application
- Diabetes Patients
- Critical Patients
- By End-User Industry
- Hospitals
- Diagnostic Centers & Clinics
- Home Care
- Others
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- Germany
- France
- United Kingdom
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- Others
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Thailand
- Others
- North America
Frequently Asked Questions (FAQs)
The continuous glucose monitoring market is expected to reach a total market size of US$17.119 billion by 2030.
Continuous Glucose Monitoring Market is valued at US$8.984 billion in 2025.
The continuous glucose monitoring market is expected to grow at a CAGR of 13.76% during the forecast period.
North America is projected to hold a major share of the continuous glucose monitoring market due to an increase in the geriatric population and surging diabetes prevalence in the region.
The demand for continuous glucose monitoring is expected to show a significant surge due to the growing prevalence of diabetes throughout the world.
1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY COMPONENT
4.1. Introduction
4.2. Sensors
4.3. Transmitters
4.4. Receivers
4.5. Integrated Insulin Pumps
5. CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY PRODUCT TYPE
5.1. Introduction
5.2. Wearable
5.3. Implantable
6. CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY APPLICATION
6.1. Introduction
6.2. Diabetes Patients
6.3. Critical Patients
7. CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY END-USER INDUSTRY
7.1. Introduction
7.2. Hospitals
7.3. Diagnostic Centers & Clinics
7.4. Home Care
7.5. Others
8. CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. Israel
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. Japan
8.6.3. India
8.6.4. South Korea
8.6.5. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Abbott Laboratories
10.2. DexCom, Inc.
10.3. Medtronic Plc
10.4. F. Hoffmann-La Roche AG
10.5. Senseonics Holdings, Inc.
Abbott Laboratories
DexCom, Inc.
Medtronic Plc
F. Hoffmann-La Roche AG
Senseonics Holdings, Inc.
Sorry, the research methodology content could not be loaded.